Anti-Hypertensive Drugs - Chile

Chile

The Anti-Hypertensive Drugs market in Chile is forecasted to generate a revenue of US$48.42m in 2024.
It is projected to experience an annual growth rate (CAGR 2024-2028) of -0.20%, leading to a market volume of US$48.04m by 2028.
When compared globally, United States is expected to generate the highest revenue, amounting to US$12,290.00m in 2024.
Chile's anti-hypertensive drug market is witnessing a surge in demand due to the country's aging population and rising prevalence of hypertension.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Chile has been experiencing steady growth in recent years.

Customer preferences: Chilean customers have been showing an increasing preference for generic drugs over branded drugs due to their lower cost. This has resulted in a shift in the market towards generic anti-hypertensive drugs. Additionally, customers are increasingly looking for drugs that have fewer side effects and are more effective in controlling hypertension.

Trends in the market: The Anti-Hypertensive Drugs market in Chile has been growing due to the increasing prevalence of hypertension in the country. The aging population and changes in lifestyle, such as increased stress levels and unhealthy diets, have contributed to the rise in hypertension cases. As a result, there has been an increase in demand for anti-hypertensive drugs. The market has also been impacted by the entry of new players, which has led to increased competition and innovation in the market.

Local special circumstances: Chile has a public healthcare system that provides free healthcare to its citizens. However, the system has limited resources and is often unable to meet the demand for healthcare services. This has led to an increase in the demand for private healthcare services, including private pharmacies. Private pharmacies have become an important distribution channel for anti-hypertensive drugs in Chile.

Underlying macroeconomic factors: The Chilean economy has been growing steadily in recent years, which has resulted in an increase in disposable income for consumers. This has led to an increase in healthcare spending, including spending on anti-hypertensive drugs. Additionally, the government has been investing in healthcare infrastructure and programs, which has led to an increase in the availability of healthcare services in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.